Key terms
About SLS
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLS news
Apr 11
8:46am ET
Largest borrow rate increases among liquid names
Apr 02
10:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
4:54pm ET
Sellas Life Sciences files to sell 13.03M shares of common stock for holders
Mar 28
4:49pm ET
Sellas Life Sciences files $200M mixed securities shelf
Mar 28
4:12pm ET
Sellas Life Sciences reports 2023 EPS ($1.34), consensus ($1.08)
Mar 28
7:06am ET
Sellas Life Sciences-licensed GFH009 included in trial combination for lymphoma
Mar 27
2:25pm ET
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
Mar 27
8:46am ET
Largest borrow rate increases among liquid names
Mar 22
8:46am ET
Largest borrow rate increases among liquid names
Mar 21
2:50pm ET
Sellas Life Sciences options imply 20.1% move in share price post-earnings
Mar 15
9:08am ET
Sellas prices 13.03M shares at $1.535 in direct offering, private placement
Mar 14
2:34pm ET
Sellas Life Sciences options imply 12.0% move in share price post-earnings
Mar 08
4:23pm ET
SELLAS Life Sciences Announces Executive Shake-up and Reorganization Strategy
Mar 08
8:11am ET
Sellas Life announces departure of CCO Francomano, General Counsel Wood
Mar 07
8:45am ET
Largest borrow rate increases among liquid names
Mar 06
8:45am ET
Largest borrow rate increases among liquid names
Mar 04
8:45am ET
Largest borrow rate increases among liquid names
Mar 01
8:35am ET
Sellas Life Sciences delivers oral presentation of SLS009 Phase 1 data
Feb 29
8:27am ET
Sellas Life Sciences to present SLS009 Phase 1 data ay 2024 ESH
Feb 26
8:45am ET
Largest borrow rate increases among liquid names
Feb 16
4:28pm ET
SELLAS Life Sciences Faces Nasdaq Minimum Bid Price Warning
Feb 08
7:07am ET
Sellas price target lowered to $7.50 from $8 at Alliance Global Partners
Feb 06
8:32am ET
Sellas Life Sciences announces publication of preclinical data on SLS009
No recent press releases are available for SLS
SLS Financials
Key terms
Ad Feedback
SLS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range